Guobang Pharma Ltd
SSE:605507
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/E
Price to Earnings (P/E) ratio shows how much investors pay for each dollar of a company`s earnings. It`s calculated by dividing the company`s market value by its total earnings.
Price to Earnings (P/E) ratio shows how much investors pay for each dollar of a company`s earnings. It`s calculated by dividing the company`s market value by its total earnings.
Valuation Scenarios
If P/E returns to its 3-Year Average (14.9), the stock would be worth ¥21.91 (8% downside from current price).
| Scenario | P/E Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 16.3 | ¥23.92 |
0%
|
| 3-Year Average | 14.9 | ¥21.91 |
-8%
|
| 5-Year Average | 15.6 | ¥22.97 |
-4%
|
| Industry Average | 25.5 | ¥37.46 |
+57%
|
| Country Average | 29.6 | ¥43.52 |
+82%
|
Forward P/E
Today’s price vs future net income
| Today's Market Cap | Net Income | Forward P/E | ||
|---|---|---|---|---|
|
¥13.6B
|
/ |
Jan 2026
¥820.8m
|
= |
|
|
¥13.6B
|
/ |
Dec 2026
¥1.3B
|
= |
|
|
¥13.6B
|
/ |
Dec 2027
¥1.4B
|
= |
|
Forward P/E shows whether today’s P/E still looks high or low once future net income are taken into account.
Peer Comparison
| Market Cap | P/E | ||||
|---|---|---|---|---|---|
| CN |
G
|
Guobang Pharma Ltd
SSE:605507
|
13.5B CNY | 16.3 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
883B USD | 42.8 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
553.5B USD | 26.3 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
216.3B GBP | 28 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
270.2B USD | 14.8 | |
| CH |
|
Novartis AG
SIX:NOVN
|
216.3B CHF | 20.7 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 11.8 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
151.8B USD | 19.5 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
122B USD | 17.3 |
Market Distribution
| Min | 0 |
| 30th Percentile | 17.1 |
| Median | 29.6 |
| 70th Percentile | 57.7 |
| Max | 43 569.3 |
Other Multiples
Guobang Pharma Ltd
Glance View
Guobang Pharma Ltd. has carved its niche within the pharmaceutical industry as an integrated player blending advanced chemical synthesis with pharmaceutical manufacturing. At its core, the company thrives on the development and production of active pharmaceutical ingredients (APIs), which are crucial components for a multitude of medications. Leveraging a robust research and development framework, Guobang Pharma consistently delivers high-quality APIs to both domestic and international clients, ensuring a steady flow of income. This strategic approach, combining a focus on innovative technology and stringent quality control, positions the company as a reliable partner in the global pharmaceutical supply chain. In addition to API production, Guobang Pharma extends its business model through the formulation and manufacturing of finished pharmaceutical products. By operating across this entire value chain, Guobang can capture a larger slice of the industry's revenue pie. The company’s diversified portfolio not only includes essential medicines but also specialty and generic drugs, allowing it to navigate market shifts and regulatory landscapes adeptly. This vertical integration enhances its competitive advantage by reducing dependency on external suppliers while contributing to its bottom line growth, as it fulfills varied market demands from development to distribution.